---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041370"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:26:32.819644+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q3 revenue $0.8M, net loss $0.16/share; Lucid revenue surges 392% sequentially

## Summary
- Q3 2023 revenue $0.8M; GAAP net loss $17.7M ($0.16 per share), non-GAAP adjusted loss $9.7M ($0.09).
- Lucid generated $783K revenue, up 392% sequentially; EsoGuard testing volumes up 17% sequentially and 137% YoY.
- Cash and equivalents $26.4M at Sept 30, down from $37.2M at June 30, reflecting ongoing cash burn.
- Veris Health launching next-gen Cancer Care Platform in Q4; on track for FDA 510(k) submission next year and implantable monitor in 2024.
- Lucid launched EsoGuard 2.0 with enhanced performance and lower per-sample costs; clinical utility data showed 98-100% concordance.

## SEC filing metadata
- accession: 0001493152-23-041370
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/0001493152-23-041370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041370
- JSON: https://secwatch.observer/filing/0001493152-23-041370.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.